Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $7.02 USD
Change Today -0.30 / -4.10%
Volume 12.8K
SBBP On Other Exchanges
As of 11:11 AM 11/30/15 All times are local (Market data is delayed by at least 15 minutes).

strongbridge biopharma plc (SBBP) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/16/15 - $14.30
52 Week Low
11/13/15 - $6.32
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

strongbridge biopharma plc (SBBP) Related Businessweek News

No Related Businessweek News Found

strongbridge biopharma plc (SBBP) Details

Strongbridge Biopharma plc, a biopharmaceutical company, through its subsidiary, Cortendo AB (publ), develops, acquires, and commercializes product candidates that target rare diseases. The company’s lead product candidate, COR-003 (levoketoconazole), is a cortisol inhibitor that is in the Phase 3 trial for the treatment of endogenous Cushing’s syndrome. It also has two product candidates, COR-004 and COR-005 in Phase 2 clinical development to treat acromegaly. In addition, it is developing BP-2001, a pre-clinical product candidate for the treatment of diabetes. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is based in Trevose, Pennsylvania.

strongbridge biopharma plc (SBBP) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $341.0K
Chief Business Officer
Total Annual Compensation: $90.8K
Chief Medical Officer
Total Annual Compensation: $14.0K
Compensation as of Fiscal Year 2014.

strongbridge biopharma plc (SBBP) Key Developments

Strongbridge Biopharma plc Presents at Arctic Biotech Seminar, Nov-30-2015 12:45 PM

Strongbridge Biopharma plc Presents at Arctic Biotech Seminar, Nov-30-2015 12:45 PM. Venue: Oslo, Norway.

Strongbridge Biopharma plc Announces New Executive Appointments

Strongbridge Biopharma plc has expanded its clinical development, regulatory affairs, operations and finance teams to help execute against the Company's strategic plans. Recently, the Company appointed Fredric Cohen, M.D., vice president, clinical research & development; James R. Englund, CPA, CMA, vice president, corporate controller; Susan Thornton, vice president, regulatory affairs; and Peter J. Valentinsson, vice president, global technical operations. Fredric Cohen, M.D., is an endocrinologist with more than 20 years of therapeutics development and related experience in the life science industry, more recently focused in rare disease and specialty products, at companies, including Aptalis Pharma, Johnson & Johnson and Eli Lilly & Company. James R. Englund, CPA, CMA, has nearly 30 years of experience in finance and accounting fields, with nearly 15 years in pharmaceutical industry finance for commercial-stage companies, including Auxilium Pharmaceuticals Inc., where he most recently served as corporate controller for nearly 10 years. Jim has also held positions at IMS Health Corporation and Aventis Behring Corporation. Susan Thornton has nearly 20 years of senior regulatory affairs experience with specialty pharmaceutical companies, including Antares Pharma, Aptalis Pharma Inc., Barrier Therapeutics and Teva Pharmaceuticals USA. Peter J. Valentinsson has more than 25 years of technical operations experience and has held positions of increasing seniority at both large pharmaceutical and biotechnology companies, including NPS Pharmaceuticals Inc.

Strongbridge Biopharma plc Presents at Stifel Healthcare Conference 2015, Nov-18-2015 04:30 PM

Strongbridge Biopharma plc Presents at Stifel Healthcare Conference 2015, Nov-18-2015 04:30 PM. Venue: The New York Palace Hotel, Hubbard Room, New York, New York, United States. Speakers: Matthew Pauls, Chief Executive Officer, President and Director.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SBBP:US $7.02 USD -0.30

SBBP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SBBP.
View Industry Companies

Industry Analysis


Industry Average

Valuation SBBP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.7x
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact STRONGBRIDGE BIOPHARMA PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at